Three of the company’s prototype genome-sequencing assays were evaluated using samples from lung cancer patients. Early support for the concept was demonstrated with detection rates ranging from 38% to 51% in participants in participants with early-stage lung cancer at 98% specificity.
The problem with the common cold is that it isn’t just one virus. It’s a family of viruses that evolve so quickly no one can ever be fully immune to the cold, and developing a vaccine that can tackle all of the variations of the virus is impossible. But what if there were one way to block the ability of all cold viruses from replicating—thereby fending off the sneezing, sore throat and general misery that they cause?
your submission has already been received.
Please enter a valid Email address！
The most relevant industry news & insight will be sent to you every two weeks.